{"id":"W2505393039","doi":"10.1007/s00345-016-1903-6","title":"Second-line treatment for metastatic clear cell renal cell cancer: experts’ consensus algorithms","year":2016,"lang":"en","type":"article","venue":"World Journal of Urology","topic":"Renal cell carcinoma treatment","field":"Medicine","cited_by":11,"is_retracted":false,"has_abstract":false,"ca_institutions":"","funders":"Bristol-Myers Squibb Canada; GlaxoSmithKline Australia; Novartis; Les Laboratories Pierre Fabre; Bayer; AstraZeneca; Merck; Novartis Pharma; Roche; Astellas Pharma US; Pfizer","keywords":"Medicine; Cabozantinib; Axitinib; Nivolumab; Everolimus; Clinical trial; Sunitinib; Intensive care medicine; Oncology; Kidney cancer; Second line treatment; Internal medicine; Tyrosine-kinase inhibitor; Cancer; Renal cell carcinoma; Chemotherapy; Immunotherapy","routes":{"ca_aff":false,"ca_fund":true,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":true},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.02397577,0.001400718,0.00378256,0.00527695,0.00156414,0.003533231,0.003980918,0.00278689,0.005734106],"category_scores_gemma":[0.04877218,0.0007689173,0.007016056,0.002754418,0.0007135934,0.003254096,0.003508626,0.004165283,0.001361585],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.005579195,"about_ca_system_score_gemma":0.01161121,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.0075706,"about_ca_topic_score_gemma":0.01388219,"domain_scores_codex":[0.9857193,0.005485741,0.003789206,0.001374043,0.003005545,0.0006260931],"domain_scores_gemma":[0.9762808,0.008373873,0.00347864,0.0008075643,0.009560309,0.001498824],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"design_other","study_design_gemma":"not_applicable","study_design_scores_codex":[0.001283597,0.000391305,0.03429432,0.01143362,0.006860965,0.0003440638,0.0005351306,0.02340645,0.0006348037,0.01579891,0.1495883,0.7554286],"study_design_scores_gemma":[0.006518304,0.00194914,0.09229741,0.07482323,0.02207134,0.00491504,0.002552163,0.1370971,0.004813713,0.1416522,0.5104594,0.0008509936],"study_design_candidate":"not_applicable","study_design_consensus":null,"genre_codex":"review","genre_gemma":"empirical","genre_scores_codex":[0.0526026,0.3826956,0.2785728,0.1507694,0.01323483,0.008196784,0.007762213,0.001743905,0.1044219],"genre_scores_gemma":[0.3792175,0.08131793,0.4820485,0.02409595,0.004003885,0.004780935,0.01800173,0.000641024,0.00589256],"genre_candidate":"empirical","genre_consensus":null,"teacher_disagreement_score":0.02397577,"threshold_uncertainty_score":0.1267974,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.04549877941455106,"score_gpt":0.3060013331278901,"score_spread":0.260502553713339,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}